Tasca Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $52M
Overview
Developing next-generation engineered T-cell therapies to treat solid tumors.
Oncology
Technology Platform
A proprietary cell engineering platform that enhances T-cell tumor infiltration, persistence, and function within the solid tumor microenvironment.
Funding History
1Total raised:$52M
PIPE$52M
Opportunities
A breakthrough in solid tumor cell therapy could capture a multi-billion dollar market segment.
Risk Factors
High technical risk of translating engineered cell function into clinical efficacy and safety in solid tumors.
Competitive Landscape
Operates in a highly competitive arena against numerous biotechs and pharma giants also developing cell therapies for solid tumors.